Citadel Advisors’s Generation Bio GBIO Stock Holding History

Citadel Advisors’s Portfolio GBIO Stock Details GBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,560	Closed	-$37K	–	13243
2025 Q2	$37K	Buy	11,560 +4,520	+64%	+$17.4K	﹤0.01%	11907
2025 Q1	$28.5K	Buy	7,040 +6,480	+1,157%	+$45.5K	﹤0.01%	12870
2024 Q4	$5.94K	Buy	+560	New	+$9.98K	﹤0.01%	13831
2024 Q3	–	Sell	-10	Closed	-$282	–	14563
2024 Q2	$282	Sell	10 -780	-99%	-$25.3K	﹤0.01%	14041
2024 Q1	$32.2K	Buy	790 +490	+163%	+$11.5K	﹤0.01%	12629
2023 Q4	$4.95K	Buy	300 +120	+67%	+$2.09K	﹤0.01%	13467
2023 Q3	$6.82K	Buy	180 +80	+80%	+$3.79K	﹤0.01%	13293
2023 Q2	$5.5K	Sell	100 -930	-90%	-$42.7K	﹤0.01%	13496
2023 Q1	$44.3K	Buy	1,030 +1,010	+5,050%	+$48.9K	﹤0.01%	12319
2022 Q4	$786	Buy	+20	New	+$1.05K	﹤0.01%	14582
2021 Q4	–	Sell	-860	Closed	-$216K	–	14145
2021 Q3	$216K	Buy	+860	New	+$206K	﹤0.01%	11826

Other funds holding GBIO

ACM

Accent Capital Management Centerville, Ohio $206M AUM 29.56% 1-Year Est. Return

Citadel Advisors's GBIO Position: Q1 2026 in Review

Citadel Advisors sold out of Generation Bio (GBIO) in Q1 2026, closing a stake of 47,245 shares — an estimated $268K sold.

Citadel Advisors first reported a position in GBIO in Q2 2020 and held it in 19 quarters. The position peaked at $11.4M in Q2 2020. 2 funds tracked by Wall St. Rank hold GBIO as of Q1 2026.

Citadel Advisors reported no remaining Generation Bio position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 47,245 Generation Bio shares in Q1 2026, an estimated $268K.
Citadel Advisors first reported a position in Generation Bio in Q2 2020 and held it in 19 quarters.
Citadel Advisors's Generation Bio position peaked at $11.4M in Q2 2020.
2 funds tracked by Wall St. Rank held Generation Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.